Glenmark Pharmaceuticals has launched bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name ‘Tavulus’ in Spain, for the treatment of chronic obstructive pulmonary disease (COPD).
Tavulus is expected to provide relief to a large patient population in the country. It is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs. It also works to prevent sudden, short-term worsening of COPD symptoms.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
